On April 1, 2026, Climb Bio, Inc. disclosed in an 8-K filing that Cindy Driscoll, the Senior Vice President of Finance and principal accounting officer, will be leaving the company effective April 30, 2026. This decision was mutual between Driscoll and the company. Following her departure, Dr. Susan Altschuller, who currently serves as the Chief Financial Officer, will take on the additional role of principal accounting officer. Dr. Altschuller has been with Climb Bio since October 2025 and has a strong background in finance, having previously held CFO positions at Dragonfly Therapeutics and Cerevel Therapeutics. The company has not indicated any changes to Dr. Altschuller's compensation plans in connection with this appointment. The leadership change may raise concerns among investors regarding the continuity of financial oversight, especially given the recent transitions in the finance department. However, the company has not reported any immediate financial impacts or operational disruptions as a result of this change.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.